Evaluation of an Information Pamphlet for Postpartum Women That Had a Hypertensive Pregnancy
Study Details
Study Description
Brief Summary
It is known that preeclampsia is a risk factor for cardiovascular diseases, diabetes, chronic hypertension, nephropathy and thromboembolism. The study's aim, subsequent to these informations, is to help prevent those consequences. Information tools have been known to enhance retention of information given orally. The objective of this study is to assess the knowledge and satisfaction of women after an episode of preeclampsia after reading an explanatory pamphlet on preeclampsia. The investigators also want to change their perception on cardiovascular risk, their risk of recurrence and preeclampsia's medium to long-term consequences and the ways to prevent them.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This is a randomised-controlled trial. Women recruted will first answer a questionnaire assessing demographic data, knowledge about risks in the future, perception of cardiovascular risk, anxiety about that risk and satisfaction about information received or collected.
Then, women in the intervention group will receive the pamphlet. One month after, women in both groups will receive a questionnaire similar to the first one assessing knowledge about risks in the future, perception of cardiovascular risk, anxiety about that risk and satisfaction about information received or collected, including the pamphlet for the intervention group.
The pamphlet was validated by a multidisciplany team including patients, doctors, nurses, education specialists and communication specialists.
The questionnaire was also validated by the same multidisciplinary team. Section on knowledge and anxiety were remodeled from previously validated questionnaires Section on perception of cardiovascular risk was reproduced and translated with permission from its author.
Section on satisfaction was reproduced from the investigators' previous study where it was validated.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Control group The control group does not receive the information pamphlet |
|
| Experimental: Intervention group The intervention group receives the information pamphlet |
Other: information pamphlet
The intervention group receives the information pamphlet
|
Outcome Measures
Primary Outcome Measures
- knowledge improvement (questionnaire with check list and true/false questions). [4 weeks]
The primary outcome will be the comparison of knowledge between the intervention (with the pamphlet) and the control (without the pamphlet) group at one month with a validated questionnaire (knowledge: check list and true/false questions).
Secondary Outcome Measures
- Perception of cardiovascular risk between the intervention and the control group at one month (Likert scale) [4 weeks]
The comparison of perception of cardiovascular risk at one month between the intervention (with the pamphlet) and the control (without the pamphlet) group with a validated Likert scale included in the questionnaire.
- Anxiety between the intervention and the control group at one month.(Likert scale) [4 weeks]
Comparison of anxiety at one month between the intervention and the control group with a validated Likert scale included in the questionnaire.
- Satisfaction between the intervention and the control group at one month.(Likert scale) [4 weeks]
Comparison of satisfaction about all sources of information at one month between the intervention and the control group with a validated Likert scale included in the questionnaire.
- Perception of cardiovascular risk in the intervention group between baseline and at one month (Likert scale) [4 weeks]
The comparison of perception of cardiovascular risk between baseline and at one month in the intervention group with a validated Likert scale included in the questionnaire.
- Perception of cardiovascular risk between baseline and at one month in the control group. (Likert scale) [4 weeks]
The comparison of perception of cardiovascular risk between baseline and at one month in the control group with a validated Likert scale included in the questionnaire.
- Anxiety in the intervention group between baseline and at one month (Likert scale) [4 weeks]
The comparison of anxiety between baseline and at one month in the intervention group with a validated Likert scale included in the questionnaire.
- Anxiety in the control group between baseline and at one month (Likert scale) [4 weeks]
The comparison of anxiety between baseline and at one month in the control group with a validated Likert scale included in the questionnaire
- Satisfaction in the intervention group between baseline and at one month(Likert scale) [4 weeks]
The comparison of satisfaction between baseline and at one month in the intervention group with a validated Likert scale included in the questionnaire.
- Satisfaction in the control group between baseline and at one month (Likert scale) [4 weeks]
The comparison of satisfaction between baseline and at one month in the control group with a validated Likert scale included in the questionnaire.
- Knowledge in the intervention group between baseline and at one month (questionnaire with check list and true/false questions). [4 weeks]
The comparison of baseline knowledge and knowledge at one month in the intervention group with a validated questionnaire (knowledge: check list and true/false questions).
- Knowledge in the control group between baseline and at one month (questionnaire with check list and true/false questions). [4 weeks]
The comparison of Baseline knowledge and knowledge at one month in the control group with a validated questionnaire (knowledge: check list and true/false questions).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years and older
-
followed at the CHUS obstetrical clinic for a 4 weeks to 18 months postpartum follow up
-
had hypertension in her last pregnancy
Exclusion criteria:
- Not able to read and write in French.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centre Hopitalier Universiatire de Sherbrooke | Sherbrooke | Quebec | Canada | J1H 5N4 |
Sponsors and Collaborators
- Université de Sherbrooke
Investigators
- Principal Investigator: Sauvé Nadine, MD, Université de Sherbrooke
- Study Chair: Anne-Marie côté, MD, Université de Sherbrooke
- Study Chair: Annabelle Cumyn, MD, Université de Sherbrooke
- Study Chair: Marie-Eve Roy-Lacroix, MD, Université de Sherbrooke
- Study Chair: Myriam Champagne, MD, Université de Sherbrooke
- Study Chair: Marie-Hélène Pesant, MD, Université de Sherbrooke
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2016-1099